What Renovia does

Renovia was a developer of prescription digital therapeutics for pelvic floor disorders, founded in 2016 and headquartered in Boston, Massachusetts. Its core product, the Leva Pelvic Health System, is a non-invasive, non-drug digital therapeutic device that delivers pelvic floor muscle training to treat urinary incontinence (including overactive bladder symptoms of urgency, frequency, and leakage) and fecal incontinence in women. The product is supported by randomized controlled trials and real-world evidence studies published in Urogynecology, and is positioned as a clinically-proven alternative to medication or surgery. The company targets two primary segments: women with pelvic health conditions, accessed via clinicians and a consumer site (LevaCares.com), and female veterans reached through federal healthcare channels including the Veterans Health Administration and VA Community Care.

The business raised approximately $72.3M across a 2017 round, a 2018 Series B (~$32.3M, led by Ascension Ventures and Perceptive Advisors), 2018 and 2020 venture debt tranches, and a 2021 Series C ($17.0M, led by Parian Global Management). Renovia ceased operations in late 2022; the Leva product line and operating activity have continued through Axena Health, Inc. (founded 2021 in Massachusetts), led by CEO and Chief Medical Officer Samantha Pulliam and VP of Consumer and Commercial Operations Annette Brewster. Under Axena, the company has expanded internationally with a Nigerian urinary incontinence feasibility study presented at FIGO 2025, joined the AgeTech Collaborative from AARP accelerator targeting women 50+, and added fecal incontinence clinical evidence via a 2026 RCT and real-world study, while maintaining a headcount of 11-50 employees and a federal procurement channel via the VHA.

Pricing is not publicly disclosed; the model is a prescription digital therapeutic sold through federal healthcare procurement and, presumably, clinical and consumer channels, with patient education and awareness marketing concentrated on LevaCares.com. The combination of a single regulated product, a small commercial team, concentrated federal distribution, and ongoing clinical evidence publications characterizes an early commercial-stage women's health Dtx business.

Name

Renovia

Legal name

Axena Health, Inc.

Website

https://renoviainc.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Renovia developed the Leva Pelvic Health System, a non-invasive, prescription digital therapeutic for women with urinary and fecal incontinence, distributed via clinicians, the LevaCares.com consumer site, and the Veterans Health Administration. Following a 2022 wind-down, the product line continues through Axena Health.

Ownership category

akta.pro rank

Product category

Digital Pelvic Health Therapeutics

NAICS

Home Health Equipment Rental (532283)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Condition-specific Digital Therapeutics (DTx) (HLACANAA)

akta.pro secondary industries

DTx/SaMD Deployment, Integration & Reimbursement Enablement (HLACANAO), Women’s Health & Fertility Therapeutics (Digital) (HLACANAK)

Keywords

• Digital therapeutics
• Pelvic floor rehabilitation
• Women's health devices
• Urinary incontinence treatment
• Fecal incontinence therapy

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Distribution channels1 record

Marketing channels1 record

Core offering

Renovia (operating through Axena Health, Inc.) develops the Leva Pelvic Health System, a prescription digital therapeutic device for women's pelvic floor rehabilitation. The system is a non-invasive, non-drug, non-surgical solution used to treat bladder leakage (including overactive bladder symptoms such as urgency, frequency, and leakage) and fecal incontinence. The product combines a sensor-based training device with educational content and a connected digital platform, supported by randomized controlled trials and real-world evidence.

Product overview

Axena Health offers the Leva Pelvic Health System, a single clinically proven non-invasive digital therapeutic product for women's pelvic health. The system provides digital pelvic floor rehabilitation therapy as a non-drug, non-surgical solution to treat urinary incontinence (bladder leakage) and fecal incontinence, backed by randomized controlled trials and real-world evidence studies published in Urogynecology.

Differentiator

Problem solved

Functional benefit

Brands

• Leva Pelvic Health System: Non-drug, non-surgical pelvic health treatment system shown to improve bladder leakage in just 4 weeks.

Products and services

• Leva Pelvic Health System A non-drug, non-surgical digital therapeutic device for women's pelvic health that provides pelvic floor rehabilitation therapy to treat bladder leakage (including overactive bladder symptoms such as leakage, urgency, frequency) and fecal incontinence. Includes enhanced educational content and is clinically proven with peer-reviewed research backing its efficacy. Targeted at women with pelvic floor disorders and female veterans receiving care through the Veterans Health Administration.

Quantifiable outcome

• Improves bladder leakage symptoms in just 4 weeks

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Carrot Fertility: Carrot provides a global fertility and reproductive health benefits platform. Comparable as a women's health employer/benefits channel that increasingly covers pelvic and continence care, making it a potential distribution partner or adjacent competitor.
• Tia: Tia operates women's health clinics combined with a digital care platform, addressing many of the same clinical conditions (urinary incontinence, pelvic floor concerns) as Axena. Comparable as a women's health brand and care-delivery model, though Tia owns in-person clinical infrastructure.
• Hologic: Hologic is a major women's health medical device and diagnostics company with deep relationships in urogynecology and pelvic floor surgical markets. Comparable as a broad incumbent whose installed base of urogynecologists could accelerate or block adoption of Leva as a non-surgical alternative.
• BD (Becton Dickinson): BD's urology and continence care portfolio (catheters, continence products) overlaps with the downstream care pathway for women treated via Leva. Comparable as a broad incumbent across female continence/urological care with significant commercial reach.
• Maven Clinic: Maven Clinic is a large digital women's health platform spanning fertility, maternity, postpartum, and menopause. While broader than Leva's narrow pelvic-floor focus, it competes for the same female-payer/employer wallet and represents a potential channel partner or competitor for women's pelvic health services.

Direct peers

• Pelvital: Pelvital's Flyte device delivers mechanotherapy for stress urinary incontinence via a prescribed at-home device, closely mirroring Leva's prescription-positioned, clinically-validated pelvic floor therapy approach. Strong direct peer on clinical positioning, prescriber channel, and female incontinence indication.
• Elvie: Elvie sells consumer-facing connected pelvic floor trainers (e.g., Elvie Trainer) targeted at postpartum and incontinence use, the same core category as the Leva Pelvic Health System. Direct overlap in product mechanism (biofeedback-based pelvic floor exercise device) and target customer (women with stress/urinary incontinence).
• Perifit: Perifit offers app-connected Kegel trainers for pelvic floor strengthening, directly competing with Leva on the consumer side. Comparable product form factor, business model (hardware + subscription content), and target demographic of women experiencing urinary incontinence.
• Atlantic Therapeutics: Atlantic Therapeutics markets INNOVO, an FDA-cleared neuromuscular electrical stimulation garment for stress urinary incontinence, competing head-to-head with Leva on mechanism, indication, and prescriber channel. Direct peer in prescription-grade pelvic floor therapy devices.

Emerging players

• Hyivy Health: Hyivy Health is developing a connected pelvic health rehabilitation device with clinical-grade outcomes tracking. Emerging peer in the same condition-specific DTx / device category as Leva, with partial overlap on pelvic floor disorders and digital measurement.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/axena-health/mycompany

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Renovia